Skip to content
Triangle logo TriangleGet started
← metastatic Soft Tissue Sarcoma

NCT00525057 · STUDY IN CONTEXT

Dalteparin in Preventing DVT in Participants With Cancer

Draft scope assessment: unclear. Attached because the study's own record describes metastatic disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Our primary outcome was the incidence of post-surgical complications, to include wound dehiscence, infection, and seroma.

Source null

→

secondary · POSTED

A secondary outcome was the occurrence of venous thrombolembolism in the post-operative period, to include both deep venous thrombosis in the lower extremity as well as pulmonary embolism.

Source null

→

secondary · POSTED

The volume of packed red blood cell transfusion in the post-operative period

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-soft-tissue-sarcoma-metastatic-30f77ca0
nct id
NCT00525057
trial label
Dalteparin in Preventing DVT in Participants With Cancer
applicability
unclear
applicability note
Attached because the study's own record describes metastatic disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
3
harms Count
2
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma-metastatic-30f77ca0
    nct id
    NCT00525057
    outcome key
    om-0000
    source section id
    NCT00525057-om-0000
    source outcome index
    0
    endpoint
    Number of Participants With Post-operative Wound Complications
    endpoint definition
    Our primary outcome was the incidence of post-surgical complications, to include wound dehiscence, infection, and seroma.
    time origin
    4 weeks after surgery
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma-metastatic-30f77ca0
    nct id
    NCT00525057
    outcome key
    om-0001
    source section id
    NCT00525057-om-0001
    source outcome index
    1
    endpoint
    Number of Participants With Occurrence of Venous Thromboembolism
    endpoint definition
    A secondary outcome was the occurrence of venous thrombolembolism in the post-operative period, to include both deep venous thrombosis in the lower extremity as well as pulmonary embolism.
    time origin
    4 weeks after surgery
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma-metastatic-30f77ca0
    nct id
    NCT00525057
    outcome key
    om-0002
    source section id
    NCT00525057-om-0002
    source outcome index
    2
    endpoint
    Post-Operative Blood Transfusion
    endpoint definition
    The volume of packed red blood cell transfusion in the post-operative period
    time origin
    4 weeks after surgery
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma-metastatic-30f77ca0
    nct id
    NCT00525057
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Interventional (Dalteparin, Metastatic)
    regimen
    Received dalteparin 5000 units daily postop, patients with metastatic disease.
    analyzed count
    25
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00525057-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma-metastatic-30f77ca0
    nct id
    NCT00525057
    outcome key
    om-0000
    arm key
    OG001
    arm label
    Interventional (Dalteparin, Sarcoma)
    regimen
    Received dalteparin 5000 units daily postop, patients with primary sarcomas.
    analyzed count
    25
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00525057-om-0000#groups/OG001
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma-metastatic-30f77ca0
    nct id
    NCT00525057
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Interventional (Dalteparin, Metastatic)
    regimen
    Received dalteparin 5000 units daily postop, patients with metastatic disease.
    analyzed count
    25
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00525057-om-0001#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma-metastatic-30f77ca0
    nct id
    NCT00525057
    outcome key
    om-0001
    arm key
    OG001
    arm label
    Interventional (Dalteparin, Sarcoma)
    regimen
    Received dalteparin 5000 units daily postop, patients with primary sarcomas.
    analyzed count
    25
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00525057-om-0001#groups/OG001
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma-metastatic-30f77ca0
    nct id
    NCT00525057
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Interventional (Dalteparin, Metastatic)
    regimen
    Received dalteparin 5000 units daily postop, patients with metastatic disease.
    analyzed count
    25
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00525057-om-0002#groups/OG000
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma-metastatic-30f77ca0
    nct id
    NCT00525057
    outcome key
    om-0002
    arm key
    OG001
    arm label
    Interventional (Dalteparin, Sarcoma)
    regimen
    Received dalteparin 5000 units daily postop, patients with primary sarcomas.
    analyzed count
    25
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00525057-om-0002#groups/OG001
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma-metastatic-30f77ca0
    nct id
    NCT00525057
    harm key
    EG000
    source section id
    NCT00525057-ae
    event group key
    EG000
    event group label
    Interventional (Dalteparin, Metastatic)
    serious affected
    1
    serious at risk
    25
    other affected
    1
    other at risk
    25
    frequency threshold
    5
    collection period
    4 weeks after surgery
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma-metastatic-30f77ca0
    nct id
    NCT00525057
    harm key
    EG001
    source section id
    NCT00525057-ae
    event group key
    EG001
    event group label
    Interventional (Dalteparin, Sarcoma)
    serious affected
    0
    serious at risk
    25
    other affected
    4
    other at risk
    25
    frequency threshold
    5
    collection period
    4 weeks after surgery
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice